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ABSTRACT
Background: Deep venous thrombosis (DVP) is a frequent disease. Prophylaxis is the best means 
to reduce its incidence, for lowering morbidity and mortality rates and treatment costs caused 
by its complications. 
Objective: To evaluate the knowledge and use of any kind of DVT prophylaxis by Brazilian Oral 
and Maxillofacial surgeons.
Materials and Methods: A questionnaire was sent to all Oral and Maxillofacial surgeons 
associated to the Brazilian College of Oral and Maxillofacial Surgeons that have a valid e-mail 
address. The data retrieved was evaluated and tabulated.
Results: Of the 1100 questionnaires sent, only 4% were retrieved. The 42 retrieved were 
included in the study. Twenty six of the surgeons do not use any kind of deep venous thrombosis 
(DVT) prophylaxis, 11 use mechanical means as elastic compressive stockings or pneumatic 
compressive devices for prophylaxis, and 5 uses low-molecular weight heparins (LMWH) as 
the choice for prophylaxis. 
Conclusion: The data collected, despite the low rate of participation (4%) by the surgeons, shows 
that this subject still does not receive proper attention. Whereas other medical specialties make 
routine use of prophylactic means maybe the maxillofacial surgeons lack concern on that matter.
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It is known that DVT could lead to critical complications, 
such as pulmonary embolism (PE) and or post-thrombosis 
syndrome.[4] Nearly 10% of the symptomatic pulmonary 
embolism leads to death in one hour after its starts, and if 
not treated, about 30% of the early treated patients with 
non-lethal pulmonary embolism would die.[5,6] The venous 
thromboembolism is mentioned as the major morbidity 
cause among hospitalized patients at the United States[6,7] 
and the PE could be the more common cause of avoidable 
mortality inside hospitals.[8]
Low-molecular weight heparins (LMWH) such as 
enoxaparin were the first-line agents recommended for the 
treatment and/or prophylaxis of thromboembolic alterations 
by the American College of Chest Physicians.[9] In Europe 
the LMWH has replaced warfarin as the standard of DVT 
prophylaxis after orthopedic procedures.[9] In spite of the 
hospital´s implementation of protocols for DVT prophylaxis 
be a major concern, the use of antithrombotic drugs is subject 
to a variety of hemorrhagic complications, such as orbital 
hemorrhagic complications in patients who had midfacial 
fractures and were receiving enoxaparin therapy presented 
in a study by Jamal et al.[10] or either a femoral nerve palsy 
after mandibular reconstruction with microvascular iliac 
flap described by Toro et al.[11]
Address for correspondence: 
Dr. Marcelo Silva Monnazzi 
E-mail: monnazzi@ig.com.br
Access this article online






Deep venous thrombosis (DVT) development depends on 
the alteration of one or more factors of the triad described 
by Virchow that considers the blood flow alterations, 
hemostasis and vascular wall as responsible for the 
emergence of DVT. After 150 years his statement remains 
true and the knowledge of relative function of any one 
of those factors made possible the comprehension of the 
thrombotic phenomenon, making easier the diagnosis 
and identification of the risk patients and helping in their 
management.[1] DVT is a frequent disease arising mainly 
as surgical and clinical complications of other diseases. 
However, it can occur spontaneously in healthy people.[2,3] 
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Regarding orthognathic operations, the venous thrombosis 
after this kind of surgery is believed to be uncommon, but 
there are a few published data to quantify the incidence after 
oral and maxillofacial operations. The incidence was estimated 
by Lowry[12] as 0,00035% based on the recall of 103 consultant 
maxillofacial surgeons in the previous 5 years. Other authors 
like Van de Perre[13] reported 3 episodes of DVT resulting in 1 
case of pulmonary embolism among 2049 patients undergoing 
orthognatic operations. However, only the complications 
occurring in the first 48 hours postoperatively were included 
in the study. Moreano et al.[14] identified 34 postoperative 
thromboembolic events after 12.805 otolaryngology and head 
and neck operations and reported that the incidence of DVT 
or PE was 0,1% after general otolaryngology operations and 
0,6% after head and neck surgery.
The THRIFT Consensus Group[15] recommended that all 
medical and surgical patients admitted to hospital should 
be assessed for risk factors [Table 1][16] and that they should 
receive proper prophylaxis related to the risk. The choice 
between mechanical or antithrombotic methods should 
depend on the balance of the risks of thromboembolism 
against bleeding in the individual patient. 
MATERIALS AND METHODS
Attempting to access the knowledge on the specific field 
and determine if and which is the DVT and PE prophylaxis 
methods of choice by the Brazilian oral and maxillofacial 
surgeons, a questionnaire was elaborated [Table 2] and it 
was send by electronic mail to all members of the Brazilian 
College of Oral and Maxillofacial Surgery.
All members that possessed an e-mail address on the 
College´s records were invited to answer 6 questions 
regarding this subject. No identification was required. The 
questions were basically yes or no answers and a few fields 
in blank were left for those who feel like to write some 
details. The members vary from senior doctors to former 
residents, so the category of the member was also asked 
at the questionnaire. About one thousand members were 
included in the research.
The answers were sent by e-mail also for the Brazilian 
College secretary and after that they were redirected to 
the responsible author´s e-mail. The data collected were 
evaluated and tabulated. 
RESULTS
The secretary of the Brazilian College sent 1100 questionnaires 
with the invitation to answer it and a brief letter specifying 
that the ones interested in answer the form had one month 
to do so, identification not being necessary. Only four 
percent (4%) of all the questionnaires sent were replied (42 
questionnaires), which were included in the study. 
After analysis and tabulation of the data retrieved we could 
find the following information on the studied samples. 
Of all 42 surgeons that answered to the questionnaire, 26 
(62%) do not routinely use any kind of drug therapy for 
the DVT prophylaxis, or any mechanical means, 5 (12%) 
do use LMWH, and 11 (26%) use only mechanical means 
[Graph 1]. Of this 5 surgeons that do use drug therapy, 3 use 
40 mg of LMWH by subcutaneous injection 1 hour prior 
to the surgery as the unique dose; one uses this same drug 
and this same dosage but with one subcutaneous injection 
12 hours preoperatively and another injection within 
24 hours postoperatively; and one surgeon uses 20 mg of 
this same drug once a day for the duration of hospitalization. 
Of the 37 surgeons that do not use LMWH as prophylactic 
measure, 11 use mechanical means for the DVT and PE 
prophylaxis, and one surgeon use LMWH and compressive 
stockings Thus, seven (7) use elastic compressive stockings 
during surgery and the hospitalization period, four (4) use 
pneumatic compressive leg devices during the surgery time 
and one (1) use pneumatic compressive leg device during the 
Table 1: Surgical patient risk groups at risk for developing 
DVT
Low risk (Without providing prophylaxis, the patient has a 1% 
chance of developing DVT and a 0.01% of developing a fatal 
pulmonary embolism)
•  Minor surgical procedures less than 30 minutes in duration
•  Patients younger than 40 years of age
•  No risk factors that would contribute to the development of DVT
•  No immobilization
Moderate risk (Without providing prophylaxis, the patient has a 10% 
chance of developing a DVT and 0.7% chance of developing a fatal 
pulmonary embolus)
•  Major surgical procedures taking longer than 60 minutes
•  Patients older than 40 years of age
•  Contributing risk factors such as cardiac disease, pulmonary 
disease, malignancy, obesity, varicose veins
•  24 hours or longer immobilization
High risk (Without providing prophylaxis, the patient has a 20% 
chance of developing a DVT and a 5% chance of developing a fatal 
pulmonary embolism)
•  Prolonged surgical procedures involving the pelvis (hip grafts). 
Lower extremities, malignancy
•  Patients older than 40 years of age
•  History of previous DVT or PE
•  Paraplegia/stroke/fractures of lower extremities/pelvis
•  Prolonged immobilization
(adapted from Solomon and Schow (1995))[16] Classification table for to 
access patients risk for developing DVT
Table 2: DVT prophylaxis in oral and maxillofacial surgery
1 -  Do you routinely use enoxaparin or any other type of 
antithrombotic drug before performs maxillofacial surgeries?
2 -  If yes at the first question please write the dosage and the 
duration of drug use.
3 -  If no at the first question please write if you use any other 
mechanical advice for the DVT prophylaxis. And if you do not use 
any kind of prevention please write why.
4 -  Knowing that other medical specialties routinely use this kind of 
drug, in which situation you would consider to use it?
5 -  Blank field for any kind of commentary
6 - Academic degree of the participant and work place.
Questionnaire sent to surgeons
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surgery and elastic compressive stockings at the remaining 
hospitalization period.
The 26 surgeons that do not use any kind of prophylactic 
means answered that the reason for this conduct is the 
following tradition of the service where they received oral 
and maxillofacial training (18 surgeons) and because they 
do not see justification at the scientific specific literature to 
use prophylaxis (8 surgeons).
When asked in which situation they would consider the use 
of LMWH as prophylactic means, the surgeons informed 
that they would do so in orthognatic surgeries (1 surgeon); 
in orthognatic and severe trauma patients and in all surgeries 
that last more than three hours (1 surgeon); in orthognatic 
surgery and in all surgeries that last more than 3 hours 
(4 surgeons); in all risk patients and in orthognatic surgery 
(1 surgeon); in all surgeries that last more than 3 hours 
(9 surgeons); in all risk patients (15 surgeons); in severe 
trauma patients and in risk patients (1 surgeon) and several 
did not answer that question (10 surgeons).
Of  all questionnaires included in this study, 26 of them were 
answered by professionals that had more than 6 years of 
practice, 10 had between 2 and 5 years of practice; 32 work 
in public hospitals and 18 in private hospitals, some of them 
work at the two types of hospitals; 11 of them are university 
professors.
DISCUSSION
Current maxillofacial scientific literature provides no 
uniform protocol on the use of LMWH in patients who 
undergo maxillofacial surgical procedures neither in 
those who have facial fractures. Probably due to the 
low incidence of DVT as a complication of maxillofacial 
surgery, which ranges from 0,00035% to 0,06%,[10,17] some 
authors recommend using the 40 mg once daily dosing, 
or, if the anticoagulation prophylaxis is contraindicated 
for any reason or it the patient can be early mobilized, he 
should receive mechanical methods for prophylaxis such 
as intermittent pneumatic compression. Those procedures 
show to decrease the risk of DVT, although they are less 
efficacious than LMWH therapy.[10,17] However, other 
studies show a higher incidence of DVT complications 
after orthognathic operations. Blackburn et al.[18] evaluated 
256 patients and 2 of them presented symptomatic DVT 
postoperatively (1,6%), confirmed by venography.
Orbital hemorrhage has been reported as a complication 
of the LMWH therapy use in patients with orbital 
or zygomatic complex fractures, and the retrobulbar 
hemorrhage is a sight-threatening emergency, because the 
orbital walls and septum form a 3-dimensional boundary, 
and the bleeding into this closed space may result in optic 
nerve compression, globe ischemia and high intraocular 
pressure.[10,12,19] Jamal et al.[10] recommend a full initial 
ophthalmologic examination in all patients with orbital 
and zygomatic fractures, and prompt reevaluation after an 
episode of emesis that could result in a sudden rise blood 
pressure, which may lead to the rupture of small orbital 
blood vessels. In the authors opinion if a high risk DVT 
patient had a facial fracture the 40 mg once daily dosage 
of LMWH rather than the twice daily dosing is advised. 
Also, if possible, dosing should be stopped 12 hours 
preoperatively and delayed 10 to 12 hours postoperatively, 
because a study examining the incidence of postoperative 
orbital hemorrhage after eyelid surgery found the greatest 
incidence to occur within the first 3 hours after the surgical 
procedure.[20]
According to Blackburn et al.,[18] nowadays it would be 
unethical to perform a study for oral and maxillofacial 
operations without any thromboprophylactic measures, 
reason that make more difficult the evaluation of the real 
necessity of LMWH therapy for those patients. One of the 
reasons that make this kind of research unethical are studies 
like the meta-analysis made by Clagett et al.,[21] that showed 
a 25% incidence of postoperative DVT after major operations 
(>30 minutes) in the absence of any prophylactic measure.
The use of graduated compression stockings during the 
general major surgery reduced the incidence of DVT from 
24,5% to 9.3% according to Clagett et al.[21] Comerota 
et al.,[22,23] showed that veins in the upper limb become 
distended during operations and this may cause vascular 
endothelial injury. Adding the loss of muscular tone and 
venous pump function, use of neuromuscular blocking 
agents, prolonged anesthesia with the venous distension 
they are factors that contribute to blood stagnation in the 
limb veins. Intermittent pneumatic compression during 
operations may reduce the incidence of DVT after major 
surgery from 9,9 to 25,1%.[21]
The pharmacological prophylaxis results in significant 
reduction in the incidence of venous thromboembolism. 
LMWH is presently generally preferred to unfractionated 
heparin because it is at least as effective and safe, can be 
given once daily and does not need to be monitored.[24] 
Graph 1: Prophylaxis used by surgeons. (1) Surgeons that do not 
use prophylaxis, (2) Use mechanical means, (3) Use pharmacological 
means
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LMWH is also less like to cause thrombocytopenia and 
osteoporosis than unfractionated heparin. One disadvantage 
of LMWH in that protamine sulphate is less effective as an 
antidote.
The bleeding risk is a clinical concern in orthognathic 
patients, but there are no data available to quantify the 
risk. Placebo-controlled trials suggest that LMWH carries 
no additional risk of major perioperative bleeding after 
hip replacement.[24] Recommended thromboprophylaxis 
in surgery state that “according to level of risk, the most 
appropriate form of prophylaxis can be selected according 
to local recommendations” according to the THRiFT II 
guidelines[25] [Table 3]. Low-risk patients have a risk of 
developing DVT of 1% or less, moderate-risk patients have 
a 10 to 40% risk of developing DVT and the high-risk group 
of patients has a 40 to 80% risk of developing it.[16]
We agree with Prandoni[26] who states that despite the 
existence of comprehensive consensus guidelines for the 
prevention and treatment of DVT, the thromboprophylaxis 
remains underused, which corroborate with our results 
of surgeons that do use any kind of prophylaxis. Reasons 
for underuse include underestimation of the risks, lack of 
awareness by the forming centers of oral and maxillofacial 
surgeons, and concerns about the risk of bleeding what 
seems to be unlikely at least theoretically. 
In the case of Brazil it is also true that intermittent 
compression devices, which would be the method of choice 
for most orthognathic surgery patients, are not available in 
many hospitals. Also, the abundant vascularization, difficult 
access to a bleeding deep bone vessel and the airway risk by 
hematoma formation in the head and neck area creates a 
doubt about routine use of LMWH in Oral and Maxillofacial 
Surgery unless systemic conditions or trauma warrant it.
In maxillofacial surgery the incidence of DVT and PE is 
low probably due to a relatively high proportion of young 
healthy patients treated in this discipline and the early 
mobilization in most cases. Nevertheless with advances in 
the specialty the risk factors of the maxillofacial surgery 
patients are increasing with the number of older and 
medically compromised patients and there can be no 
justification to withhold prophylaxis when indicated, 
whether pharmacological or mechanical. Further studies 
on this field are required; however the patients should not 
be exposed to DVT risk in spite the low incidence. Risk 
classification should be assessed prior to surgical procedures 
and proper prophylaxis used when indicated. Teaching 
programs should provide the necessary information and 
training on the matter for their residents.  
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